PDF herunterladen
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2021; 79(07): 624-629
DOI: 10.1590/0004-282X-ANP-2020-0407
View and Review

Myasthenia gravis during pregnancy: what care should be taken?

Miastenia gravis durante a gestação: quais cuidados devem ser realizados?
Renata Dal-Prá Ducci 
1   Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Cláudia Suemi Kamoi Kay 
1   Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Otto Jesus Hernandez Fustes 
1   Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Lineu Cesar Werneck 
1   Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Paulo José Lorenzoni 
1   Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Rosana Herminia Scola 
1   Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Myasthenia gravis (MG) is an autoimmune disease in which the peak incidence is among women of childbearing age. For this reason, there is an overlap between the occurrence of this disease and pregnancy. It is known that MG symptoms can worsen during pregnancy and postpartum, and that pregnancy has special characteristics in MG patients. Children born to myasthenic mothers are at risk of having transient neonatal myasthenia. We briefly review the main relationships between MG and pregnancy, and we make recommendations for MG therapy, pregnancy, delivery, breastfeeding and newborns.

Resumo

Miastenia gravis (MG) é uma doença autoimune cujo pico de incidência nas mulheres coincide com a idade fértil. Por esse motivo, existe uma sobreposição entre a ocorrência desta doença com a gestação. Sabe-se que os sintomas da MG podem piorar durante a gestação e no puerpério, e que a gestação possui características especiais em pacientes com MG. Existe também um risco de miastenia neonatal transitória em recém-nascidos de gestantes miastênicas. Nós revisamos brevemente as principais relações entre MG e gestação, e realizamos recomendações para o tratamento da MG durante a gestação, os cuidados durante a gravidez, incluindo a via de parto, e com o recém-nascido e com a amamentação.

Keywords:

Myasthenia gravis - Pregnancy - Delivery - Breastfeeding - Transient Neonatal Myasthenia - Therapy

Palavras-chaves:

Miastenia gravis - Gestação - Via de parto - Amamentação - Miastenia Neonatal Transitória - Tratamento

Authors’ contributions:

All authors worked extensively on the manuscript and all approved this submitted version. The authors Renata-Prá Ducci and Paulo José Lorenzoni conceived the idea for the article, which was written by Renata Dal-Prá Ducci and critically reviewed by all authors.




Publikationsverlauf

Eingereicht: 28. September 2020

Angenommen: 21. Oktober 2020

Artikel online veröffentlicht:
01. Juni 2023

© 2021. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Cunha FM, Scola RH, Werneck LC. Myasthenia Gravis: clinical evaluation of 153 patients. Arq Neuropsiquiatr. 1999 Jun;57(2B):457-64. https://doi.org/10.1590/S0004-282X1999000300018
  • 2 Waters J. Management of Myasthenia Gravis in Pregnancy. Neurol Clin. 2019 Feb;37(1):113-20. https://doi.org/10.1016/j.ncl.2018.09.003
  • 3 Aguiar A de AX, Carvalho AF, Costa CM de C, et al. Myasthenia gravis in Ceará, Brazil: clinical and epidemiological aspects. Arq Neuropsiquiatr. 2010 Dec;68(6):843-8. https://doi.org/10.1590/S0004-282X2010000600003
  • 4 Ohlraun S, Hoffmann S, Klehmet J, et al. Impact of myasthenia gravis on family planning: How do women with myasthenia gravis decide and why? Muscle Nerve. 2015 Sep;52(3):371-9. https://doi.org/10.1002/mus.24556
  • 5 Hamel J, Ciafaloni E. An Update: Myasthenia Gravis and Pregnancy. Neurol Clin. 2018 May;36(2):355-65. https://doi.org/10.1016/j.ncl.2018.01.005
  • 6 Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology. 2003 Nov 25;61(10):1362-6. https://doi.org/10.1212/01.WNL.0000082725.21444.EC
  • 7 Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007 Jan;14(1):38-43. https://doi.org/10.1111/j.1468-1331.2006.01538.x
  • 8 Boldingh MI, Maniaol AH, Brunborg C, et al. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology. 2016 Nov 15;87(20):2139-45. https://doi.org/10.1212/WNL.20200407202004073339
  • 9 Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26;87(4):419-25. https://doi.org/10.1212/WNL.20200407202004072790
  • 10 Ciafaloni E, Massey JM. Myasthenia gravis and pregnancy. Neurol Clin. 2004 Nov;22(4):771-82. https://doi.org/10.1016/j.ncl.2004.06.003
  • 11 Ducci RD, Lorenzoni PJ, Kay CS, et al. Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscul Disord. 2017 Apr;27(4):352-7. https://doi.org/10.1016/j.nmd.2017.01.021
  • 12 Batocchi AP, Majolini L, Evoli A, et al. Course and treatment of myasthenia gravis during pregnancy. Neurology. 1999 Feb;52(3):447-52. https://doi.org/10.1212/WNL.52.3.447
  • 13 Brenner T, Beyth Y, Abramsky O. Inhibitory effect of alpha-fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor. Proc Natl Acad Sci USA. 1980 Jun;77(6):3635-9. https://doi.org/10.1073/pnas.77.6.3635
  • 14 Varner M. Myasthenia gravis and pregnancy. Clin Obstet Gynecol. 2013 Jun;56(2):372-81. https://doi.org/10.1097/GRF.0b013e31828e92c0
  • 15 Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry. 2014 May;85(5):538-43. https://doi.org/10.1136/jnnp-2013-305572
  • 16 Braga AC, Pinto C, Santos E, Braga J. Myasthenia gravis in pregnancy: Experience of a portuguese center. Muscle Nerve. 2016 Oct;54(4):715-20. https://doi.org/10.1002/mus.25095
  • 17 Roth TC, Raths J, Carboni G, et al. Effect of pregnancy and birth on the course of myasthenia gravis before or after transsternal radical thymectomy. Eur J Cardiothorac Surg. 2006 Feb;29(2):231-5. https://doi.org/10.1016/j.ejcts.2005.11.022
  • 18 Tanacan A, Fadiloglu E, Ozten G, et al. Myasthenia gravis and pregnancy: retrospective evaluation of 27 pregnancies in a tertiary center and comparison with previous studies. Ir J Med Sci. 2019 Nov;188(4):1261-7. https://doi.org/10.1007/s11845-019-02029-0
  • 19 Hassan A. Myasthenia gravis and preeclampsia: Dot all the I's and cross all the T's. J Taibah Univ Med Sci. 2017 May 5;12(5):461-4. https://doi.org/10.1016/j.jtumed.2017.01.006
  • 20 Ozcan J, Balson IF, Dennis AT. New diagnosis myasthenia gravis and preeclampsia in late pregnancy. BMJ Case Rep. 2015 Feb 26;2015:bcr2014208323. https://doi.org/10.1136/bcr-2014-208323
  • 21 Sikka P, Joshi B, Aggarwal N, et al. Distinguishing Myasthenia Exacerbation from Severe Preeclampsia: A Diagnostic and Therapeutic Challenge. J Clin Diagn Res. 2015 Aug;9(8):QD05-6. https://doi.org/10.7860/JCDR/2015/12789.6357
  • 22 Ferrero S, Pretta S, Nicoletti A, et al. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):129-38. https://doi.org/10.1016/j.ejogrb.2005.01.002
  • 23 Mitchell PJ, Bebbington M. Myasthenia gravis in pregnancy. Obstet Gynecol. 1992 Aug;80(2):178-81.
  • 24 Djelmis J, Sostarko M, Mayer D, Ivanisevic M. Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol. 2002 Aug 5;104(1):21-5. https://doi.org/10.1016/S0301-2115(02)00051-9
  • 25 Téllez-Zenteno JF, Hernández-Ronquillo L, Salinas V, et al. Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. BMC Musculoskelet Disord. 2004 Nov 16;5:42. https://doi.org/10.1186/1471-2474-5-42
  • 26 Tsurane K, Tanabe S, Miyasaka N, et al. Management of labor and delivery in myasthenia gravis: A new protocol. J Obstet Gynaecol Res. 2019 May;45(5):974-80. https://doi.org/10.1111/jog.13922
  • 27 Edmundson C, Guidon AC. Neuromuscular Disorders in Pregnancy. Semin Neurol. 2017 Dec;37(6):643-52. https://doi.org/10.1055/s-0037-1608785
  • 28 Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998 Jul;58(1):2-5. https://doi.org/10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4
  • 29 Bansal R, Goyal MK, Modi M. Management of myasthenia gravis during pregnancy. Indian J Pharmacol. 2018 Nov-Dec;50(6):302-8. https://doi.org/10.4103/ijp.IJP_452_17
  • 30 Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002 May;65(5):240-61. https://doi.org/10.1002/tera.10043
  • 31 Gilhus NE, Hong Y. Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol. 2018 Dec;25(12):1402-9. https://doi.org/10.1111/ene.13788
  • 32 US Food & Drug Administration. Pregnancy categories, drug safety and availability. [Internet] US Food & Drug Admnistration; 2020 [cited 2020 Feb 15]. Available from: https://www.fda.gov/Drugs/default.htm
  • 33 Ministério da Saúde. Resolução da Diretoria Colegiada - RDC Nº 60, de 17 de dezembro de 2010. [Internet]. Agência Nacional de Vigilância Sanitária; 2010 [cited 2020 May 2]. 69p. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/rdc0060_17_12_2010.pdf
  • 34 Dogan NU, Uysal II, Fazliogullari Z, et al. Investigation of developmental toxicity and teratogenicity of cyclosporine A, tacrolimus and their combinations with prednisolone. Regul Toxicol Pharmacol. 2016 Jun;77:213-22. https://doi.org/10.1016/j.yrtph.2016.03.010
  • 35 Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000 Dec 27;70(12):1718-21. https://doi.org/10.1097/00007890-200012270-00010
  • 36 Ministério da Saúde; Secretaria da Atenção à Saúde; Departamento de Ações Programáticas e Estratégicas. Amamentação e uso de medicamentos e outras substâncias. 2nd ed. Brasília (DF): Ministério da Saúde; 2014.
  • 37 Stieglbauer K, Pichler R, Topakian R. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential. J Neurol Sci. 2017 Apr 15;375:241-4. https://doi.org/10.1016/j.jns.2017.02.009
  • 38 Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic Syndromes. Continuum (Minneap Minn). 2019 Dec;25(6):1767-84. https://doi.org/10.1212/CON.20200407202004070800
  • 39 Gamez J, Salvado M, Casellas M, et al. Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy. J Neurol Sci. 2017 Dec 15;383:118-22. https://doi.org/10.1016/j.jns.2017.10.037
  • 40 Colpo A, Marson P, Pavanello F, et al. Therapeutic apheresis during pregnancy: A single center experience. Transfus Apher Sci. 2019 Oct;58(5):652-8. https://doi.org/10.1016/j.transci.2019.07.009
  • 41 Marson P, Gervasi MT, Tison T, et al. Therapeutic apheresis in pregnancy: General considerations and current practice. Transfus Apher Sci. 2015 Dec;53(3):256-61. https://doi.org/10.1016/j.transci.2015.11.004
  • 42 Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient. J Clin Apher. 2017 Jun;32(3):191-5. https://doi.org/10.1002/jca.21468
  • 43 Lorenzoni PJ, Comerlato EA, Scola RH. Crise miastênica: aspectos clínicos e manejo inicial. In: Teive HAG, Nóvak EM, Lange MC. Condutas em Emergências Neurológicas - diagnóstico e tratamento. 2nd. São Paulo(SP): Segmento Farma; 2011. 180-94.
  • 44 Townsel C, Keller R, Johnson K, et al. Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis. AJP Rep. 2016 Mar;6(1):e133-6. https://doi.org/10.1055/s-0036-1579624
  • 45 Santos E, Braga A, Gabriel D, et al. MuSK myasthenia gravis and pregnancy. Neuromuscul Disord. 2018 Feb;28(2):150-3. https://doi.org/10.1016/j.nmd.2017.11.014
  • 46 Hoff JM, Daltveit AK, Gilhus NE. Asymptomatic myasthenia gravis influences pregnancy and birth. Eur J Neurol. 2004 Aug;11(8):559-62. https://doi.org/10.1111/j.1468-1331.2004.00900.x
  • 47 Riemersma S, Vincent A, Beeson D, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest. 1996 Nov 15;98(10):2358-63. https://doi.org/10.1172/JCI119048
  • 48 Madi A, Bransburg-Zabary S, Maayan-Metzger A, et al. Tumor-associated and disease-associated autoantibody repertoires in healthy colostrum and maternal and newborn cord sera. J Immunol. 2015 Jun 1;194(11):5272-81. https://doi.org/10.4049/jimmunol.1402771
  • 49 Durst JK, Rampersad RM. Pregnancy in women with solid-organ transplants: A review. Obstet Gynecol Surv. 2015 Jun;70(6):408-18. https://doi.org/10.1097/OGX.20200407202004070194